[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Crona, D.J., and Whang, Y.E. (2017) Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. Cancers (Basel), 9, Article 67. https://doi.org/10.3390/cancers9060067
|
[3]
|
Korpal, M., Korn, J.M., Gao, X., et al. (2013) An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). Cancer Discovery, 3, 1030-1043.
https://doi.org/10.1158/2159-8290.CD-13-0142
|
[4]
|
Branch, J.R., Bush, T.L., Pande, V., et al. (2021) Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 20, 763-774.
https://doi.org/10.1158/1535-7163.MCT-20-0510
|
[5]
|
Takeda, D.Y., Spisak, S., Seo, J.H., et al. (2018) A Somat-ically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell, 174, 422-432e13. https://doi.org/10.1016/j.cell.2018.05.037
|
[6]
|
Bohl, C.E., Gao, W., Miller, D.D., et al. (2005) Struc-tural Basis for Antagonism and Resistance of Bicalutamide in Prostate Cancer. Proceedings of the National Academy of Sciences of the United States of America, 102, 6201-6206.
https://doi.org/10.1073/pnas.0500381102
|
[7]
|
Bubley, G.J., and Balk, S.P. (2017) Association between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 2103-2105. https://doi.org/10.1200/JCO.2017.72.8808
|
[8]
|
Kocak, A., and Yildiz, M. (2022) Molecular Dynamics Simulations Reveal the Plausible Agonism/Antagonism Mechanism by Steroids on Androgen Receptor Mutations. Journal of Molec-ular Graphics and Modelling, 111, Article ID: 108081. https://doi.org/10.1016/j.jmgm.2021.108081
|
[9]
|
Balbas, M.D., Evans, M.J., Hosfield, D.J., et al. (2013) Overcoming Mutation-Based Resistance to Antiandrogens with Rational Drug Design. eLife, 2, e00499. https://doi.org/10.7554/eLife.00499
|
[10]
|
Arora, V.K., Schenkein, E., Murali, R., et al. (2013) Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell, 155, 1309-1322. https://doi.org/10.1016/j.cell.2013.11.012
|
[11]
|
Farrow, J.M., Yang, J.C. and Evans, C.P. (2014) Autophagy as a Modulator and Target in Prostate Cancer. Nature Reviews Urology, 11, 508-516. https://doi.org/10.1038/nrurol.2014.196
|
[12]
|
Hoshi, S., Meguro, S., Imai, H., et al. (2021) Upregulation of Gluco-corticoid Receptor-Mediated Glucose Transporter 4 in Enzalutamide-Resistant Prostate Cancer. Cancer Science, 112, 1899-1910. https://doi.org/10.1111/cas.14865
|
[13]
|
Serritella, A.V., Shevrin, D., Heath, E.I., et al. (2022) Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Pros-tate Cancer. Clinical Cancer Research, 28, 1549-1559.
https://doi.org/10.1158/1078-0432.CCR-21-4049
|
[14]
|
Adelaiye-Ogala, R., Gryder, B.E., Nguyen, Y.T.M., et al. (2020) Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocor-ticoid Receptor. Molecular Cancer Therapeutics, 19, 1436-1447.
https://doi.org/10.1158/1535-7163.MCT-19-0936
|
[15]
|
Kurmis, A.A., Yang, F., Welch, T.R., et al. (2017) A Pyr-role-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer. Cancer Research, 77, 2207-2212. https://doi.org/10.1158/0008-5472.CAN-16-2503
|
[16]
|
Cheng, K., Liu, X., Chen, L., et al. (2018) Alpha-Viniferin Activates Autophagic Apoptosis and Cell Death by Reducing Glucocorticoid Receptor Expression in Castration-Resistant Prostate Cancer Cells. Medical Oncology, 35, Article No. 105. https://doi.org/10.1007/s12032-018-1163-y
|
[17]
|
Rosette, C., Agan, F.J., Rosette, N., et al. (2020) The Dual An-drogen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors That Have Ac-quired GR-Mediated Resistance to AR Blockade. Molecular Cancer Therapeutics, 19, 2256-2266. https://doi.org/10.1158/1535-7163.MCT-19-1137
|
[18]
|
Ide, H., Inoue, S., Mizushima, T., et al. (2020) Compound A Inhibits Urothelial Tumorigenesis via both the Androgen Receptor and Glucocorticoid Receptor Signaling Pathways. American Journal of Translational Research, 12, 1779-1788.
|